Health Condition 1: D50- Iron deficiency anemia
Conditions
Interventions
Intervention1: Ferrous fumarate: Ferrous fumarate 200mg Once Daily
Control Intervention1: Ferrous sulphate: Ferrous sulphate 200 mg Once Daily
Sponsors
JIPMER, Puducherry
Eligibility
Inclusion criteria
Inclusion criteria: Newly diagnosed patients with iron deficiency anemia of either sex Iron deficiency anemia is defined as Hemoglobin concentration between 6-10g/dl, serum ferritin concentration of less than 30 microgram/L and peripheral blood picture consistent with iron deficiency anemia
Exclusion criteria
Exclusion criteria: Patients with iron deficiency anemia with cardiac failure Pregnant and lactating women Patient who has already been diagnosed to have iron deficiency anemia and receiving oral iron therapy Patients requiring urgent blood transfusion for anemia Patients with known allergy to ferrous sulphate or ferrous fumarate Patients known to have thalassemia Patients known to have malabsorption syndrome Patients known to have peptic ulcer disease Patients known to have coronary artery disease Patients known to have chronic kidney disease with serum creatinine of more than 2mg/dL Patients known to have liver disease Alcohol abuse with Alcohol intake of more than once per week Overt Gastrointestinal bleeding Patient who received acid suppressive therapy for more than 1 month Dimorphic or Megaloblastic picture on peripheral smear examination Patients known to have Anemia of chronic disease secondary to systemic lupus erethematousus, inflammatory bowel disease, HIV, Tuberculosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the haemoglobin increment with low-dose ferrous sulphate (once daily 200 mg tablet, with 60mg elemental iron) and ferrous fumarate (once daily 200 mg tablet with 64mg elemental iron) treatmentsTimepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessing the adverse effects related to low-dose ferrous sulphate and ferrous fumarate treatments Assessing the treatment compliance between the two armsTimepoint: 2 weeks, 4 weeks, 8 weeks and 12 weeks;To compare the haemoglobin increment with low-dose ferrous sulphate and ferrous fumarate treatmentsTimepoint: 2 weeks, 8 weeks and 12 weeks | — |
Countries
India
Contacts
Public ContactVinod K V
JIPMER
Outcome results
None listed